The Career Track Starts Here

“Oh, yes. I remember my PharmD project,” says Paul Abramowitz, PharmD’79, RE’79, director of the Department of Pharmaceutical Care at University of Iowa Hospitals and Clinics, and professor in the University of Iowa College of Pharmacy.

“That was the first honest-to-goodness research project I had done. I not only learned an immense amount from that project, but my classmate Mirza Perez, PharmD’79, and I got it published in the Journal of Allergy and Clinical Immunology, at that time the top medical journal in its specialty area. The data we collected was good, and that study still stands up to scrutiny 24 years later. My PharmD project was, and continues to be, a source of personal pride.”

The project, precepted by Professor of Pharmacy Cary Johnson, who is not much older than Abramowitz, examined the extent to which two drugs — aminophylline and terbutaline — then commonly used to treat asthmatic patients, affected skin-test response.

“At that time, patients diagnosed with asthma and stabilized on medications were sent to an allergist for skin testing,” Abramowitz explains. “The assumption was that these two drugs inhibited skin-test reactions, thus producing false negatives. So what allergists sometimes did was to stop the drugs for a period of a week before they did the skin test so they could get a true skin-test response. In the meantime, some patients had significant asthma symptom flare-up, sometimes necessitating an emergency room visit.”

What the study revealed was that aminophylline and terbutaline, singly or in combination, did not inhibit the re-lease of histamine and thus did not affect skin-test response. The result: A significant change in practice following publication of the study.

“It was much more than Mirza and I thought we could accomplish, although I think that Cary knew it could be very significant all along,” confides Abramowitz, who has published and lectured extensively in the years since, mainly about the ways pharmaceutical care can improve patient care outcomes. “My PharmD project taught me research methodology by actually doing it. It also gave me a greater appreciation of what patients go through in a clinical trial. The end result was that I became a better pharmacist and clinician.

“There was a lot of learning involved with the project — much more so than I anticipated when Cary, Mirza, and I first discussed it,” Abramowitz adds. “But seeing the project to completion taught me a lot about myself. Before my PharmD project, if you had told me I was capable of doing a piece of research worthy of publication in the Journal of Allergy and Clinical Immunology, I would have thought, ‘No way.’ The thing is, once you’ve done a research project, you realize you can do it.

“If I had never been exposed to doing research — that is, if I had only studied it, as is the more common practice in pharmacy schools — I’m not certain I would have understood how new and novel pharmacy services impact patient care outcomes. That’s been a major component of my career.”

Building on Firm Foundations
PharmD Investigations Project Puts Theory to Work
Advancing the Project Cycle
The Challenges
Up Close: P-4 Current Investigations Project 1
Up Close: P-4 Current Investigations Project 2
Alumni Report: Stay the Course
Sitemap | Feedback | Faculty&Staff Intranet | University of Michigan
428 Church Street / Ann Arbor, MI 48109-1065 / (734) 764-7312
©2003 / page last modified: Thursday, 13-Mar-2003 09:48:11 EST